Huntington's disease biomarker hunt: spinal fluid study seeks clues
NCT ID NCT04012411
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at a protein called BDNF, which helps keep brain cells healthy, in people with Huntington's disease. Researchers will measure BDNF and related markers in spinal fluid and blood, and compare them to healthy controls. The goal is to find biological signs that could track the disease and guide future treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this study could identify reliable biomarkers for Huntington's disease progression and point toward new treatment targets.
- What could go wrong
- This is an observational study, not a treatment trial. It is early-stage research focused on understanding the disease, so there is no direct benefit to participants.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HUNTINGTON DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University Hospital of Montpellier
RECRUITINGMontpellier, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a genetic 'Patch' fix Huntington's disease? lab test aims to find out
- Could a brain disease change behavior years before diagnosis?
- Scientists decode gait signatures to spot brain diseases
- Can a One-Page guide spark better End-of-Life talks for dementia patients?
- Blood test could spot Parkinson's earlier, study hopes
- Can a cooking oil protect the brain in Huntington's?